Technical Analysis for BCAB - BioAtla, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.00% | |
| Crossed Above 50 DMA | Bullish | 0.00% | |
| MACD Bullish Centerline Cross | Bullish | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Earnings Movers | Other | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| 20 DMA Resistance | Bearish | 14.94% | |
| 50 DMA Resistance | Bearish | 14.94% | |
| MACD Bearish Centerline Cross | Bearish | 14.94% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 17 hours ago |
| 2x Volume Pace | about 17 hours ago |
| 1.5x Volume Pace | about 17 hours ago |
| 3x Volume Pace | about 17 hours ago |
| 5x Volume Pace | about 17 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/14/2024
BioAtla, Inc., a biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of various cancers. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. It also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. The company was founded in 2007 and is based in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Bladder Cancer Hepatocellular Carcinoma NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Drugs Health Care Tumor Cancer Immunotherapy Monoclonal Antibodies Non Small Cell Lung Cancer Melanoma Small Cell Lung Cancer Targeted Therapy Bladder Cancer Hepatocellular Carcinoma NSCLC Non Small Cell Lung Carcinoma Renal Cell Carcinoma Cervical Cancer Gastric Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.02 |
| 52 Week Low | 1.24 |
| Average Volume | 709,150 |
| 200-Day Moving Average | 2.30 |
| 50-Day Moving Average | 2.86 |
| 20-Day Moving Average | 2.70 |
| 10-Day Moving Average | 2.97 |
| Average True Range | 0.37 |
| RSI (14) | 53.27 |
| ADX | 17.0 |
| +DI | 24.87 |
| -DI | 18.94 |
| Chandelier Exit (Long, 3 ATRs) | 2.43 |
| Chandelier Exit (Short, 3 ATRs) | 3.10 |
| Upper Bollinger Bands | 3.49 |
| Lower Bollinger Band | 1.91 |
| Percent B (%b) | 0.69 |
| BandWidth | 58.72 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0017 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.66 | ||||
| Resistance 3 (R3) | 3.65 | 3.41 | 3.55 | ||
| Resistance 2 (R2) | 3.41 | 3.25 | 3.42 | 3.51 | |
| Resistance 1 (R1) | 3.21 | 3.14 | 3.31 | 3.22 | 3.48 |
| Pivot Point | 2.97 | 2.97 | 3.03 | 2.98 | 2.97 |
| Support 1 (S1) | 2.77 | 2.81 | 2.87 | 2.78 | 2.52 |
| Support 2 (S2) | 2.53 | 2.70 | 2.54 | 2.49 | |
| Support 3 (S3) | 2.33 | 2.53 | 2.45 | ||
| Support 4 (S4) | 2.34 |
